|Place of Origin:||China|
|Certification:||GMP, ISO 9001, USP|
|Model Number:||CAS 54965-24-1|
|Minimum Order Quantity:||Free samples Available|
|Packaging Details:||as your required|
|Delivery Time:||3-7 working days|
|Payment Terms:||Western Union, MoneyGram, T/T, Bitcoin|
|Supply Ability:||500 kg / month|
|Storage:||Shading, Confined Preservation||Usage:||Anti-estrogen Fertility Inducer|
|Appearance:||White Crystalline Powder||Email:||Tonyraws810@gmail.com|
anti estrogen supplements for men,
natural anti estrogen
Tamoxifen / Nolvadex Anti-Estrogen Fertility Inducer CAS 54965-24-1
CAS : 54965-24-1
MP: 140-144 ºC
Appearance: white crystalline powder
Storage: Shading, confined preservation
Drug Class: Anabolic Androgenic Steroid
Usage: the goods to anti-estrogen fertility inducer, the objects indysfunctional uterine bleeding, polycystic ovary, menstrual disorders and drug-induced amenorrhea and other gynecologic diseases;It is used as a first line defense against breast cancer.
Tamoxifen (TMX), sold under the brand name Nolvadex among others, is a medication that is used to prevent breast cancer in women and treat breast cancer in women and men.It is also being studied for other types of cancer. It has been used for Albright syndrome. Tamoxifen is typically taken daily by mouth for five years for breast cancer.
Serious side effects include a small increased risk of uterine cancer, stroke, vision problems, and pulmonary embolism. Common side effects include irregular periods, weight loss, and hot flashes. It may cause harm to the baby if taken during pregnancy or breastfeeding. It is a selective estrogen-receptor modulator (SERM) that works both by decreasing factors that increase the growth of breast cells and increasing factors that decrease the growth of breast cells.It is of the triphenylethylene group.
Tamoxifen was discovered in 1967. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. Tamoxifen is available as a generic medication.
Tamoxifen is currently used for the treatment of both early and advanced estrogen receptor (ER)-positive (ER+) breast cancer in pre- and post-menopausal women. Additionally, it is the most common hormone treatment for male breast cancer. It is also approved by the FDA for the prevention of breast cancer in women at high risk of developing the disease. It has been further approved for the reduction of contralateral (in the opposite breast) cancer. The use of tamoxifen is recommended for 10 years.
In 2006, the large STAR clinical study concluded that raloxifene is equally effective in reducing the incidence of breast cancer, but after an average 4-year follow-up there were 36% fewer uterine cancers and 29% fewer blood clots in women taking raloxifene than in women taking tamoxifen, although the difference was not statistically significant.
Tamoxifen is used to treat infertility in women with anovulatory disorders. It is given at days 3–7 of a woman's cycle.
Tamoxifen improves fertility in males with infertility by disinhibiting the hypothalamic-pituitary-adrenal axis (via ER antagonism) and thereby increasing the secretion of luteinizing hormone and follicle-stimulating hormone and increasing testicular testosterone production.
Tamoxifen is used to prevent estrogen-related gynecomastia, resulting from elevated estrogenic levels. It is taken as a preventative measure in small doses, or used at the onset of any symptoms such as nipple soreness or sensitivity. Other drugs are taken for similar purposes such as clomiphene citrate and the anti-aromatase drugs which are used in order to try to avoid the hormone-related adverse effects. Tamoxifen is also sometimes used to treat or prevent gynecomastia in sex offenders undergoing temporary chemical castration.
Occasionally tamoxifen is used in treatment of the rare conditions of retroperitoneal fibrosis and idiopathic sclerosing mesenteritis.
|Product name||Tamoxifen citrate (Nolvadex)|
|Appearance||White crystalline powder|
|Identification||IR , UV conform||Conform|
|Loss on drying||≤0.5ml||0.29ml|
|Residue on ignition||Not more than 0.2%||0.07ml|
|Iron||Not more than 0.005%||0.0027%|
|Heavy metals||Not more than 0.001%||0.0006%|
|Related substances||Total: Not more than 1.0%
Individual: Not more than 0.5%
|E-isomer||Not more than 0.3%||0.12%|
|Organic volatile impurities||Conforms||Conforms|
Any needs, please contact me